Display options
Cite
Pellini R, Venuti A, Pimpinelli F, et al. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines (Basel). 2021;9(7)doi: 10.3390/vaccines9070685.
Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., De Virgilio, A., De Marco, F., Di Domenico, E. G., Di Bella, O., Di Martino, S., Ensoli, F., Giannarelli, D., Mandoj, C., Manciocco, V., Marchesi, P., Mazzola, F., Moretto, S., Petruzzi, G., Petrone, F., Pichi, B., Pontone, M., Zocchi, J., Vidiri, A., Vujovic, B., Piaggio, G., Morrone, A., & Ciliberto, G. (2021). Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines, 9(7), . https://doi.org/10.3390/vaccines9070685
Pellini, Raul, et al. "Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI." Vaccines vol. 9,7 (2021). doi: https://doi.org/10.3390/vaccines9070685
Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, De Virgilio A, De Marco F, Di Domenico EG, Di Bella O, Di Martino S, Ensoli F, Giannarelli D, Mandoj C, Manciocco V, Marchesi P, Mazzola F, Moretto S, Petruzzi G, Petrone F, Pichi B, Pontone M, Zocchi J, Vidiri A, Vujovic B, Piaggio G, Morrone A, Ciliberto G. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. Vaccines (Basel). 2021 Jun 22;9(7). doi: 10.3390/vaccines9070685. PMID: 34206312; PMCID: PMC8310011.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2021 Jun 22;9(7). doi: 10.3390/vaccines9070685.

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI.

Vaccines

Raul Pellini, Aldo Venuti, Fulvia Pimpinelli, Elva Abril, Giovanni Blandino, Flaminia Campo, Laura Conti, Armando De Virgilio, Federico De Marco, Enea Gino Di Domenico, Ornella Di Bella, Simona Di Martino, Fabrizio Ensoli, Diana Giannarelli, Chiara Mandoj, Valentina Manciocco, Paolo Marchesi, Francesco Mazzola, Silvia Moretto, Gerardo Petruzzi, Fabrizio Petrone, Barbara Pichi, Martina Pontone, Jacopo Zocchi, Antonello Vidiri, Branka Vujovic, Giulia Piaggio, Aldo Morrone, Gennaro Ciliberto

Affiliations

  1. Department Otolaryngology Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  2. HPV Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  3. Department of Microbiology and Virology, IRCCS San Gallicano Dermatological Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  4. Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  5. Department Clinical Pathology and Cancer Biobank, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  6. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy.
  7. Department of RiDAIT, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  8. Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  9. Department of Pathology, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  10. Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  11. U.O.C. D.I.T.R.A.R. IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  12. Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  13. UOSD SAFU, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  14. Scientific Direction, IRCCS San Gallicano Dermatological Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
  15. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.

PMID: 34206312 PMCID: PMC8310011 DOI: 10.3390/vaccines9070685

Abstract

BACKGROUND: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI).

METHODS: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose.

RESULTS: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47-56

CONCLUSIONS: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.

Keywords: COVID-19; SARS-CoV-2; antibodies; obesity; serum titer; vaccine

References

  1. Euro Surveill. 2021 Feb;26(6): - PubMed
  2. Blood. 2011 Aug 4;118(5):1305-15 - PubMed
  3. Nature. 2020 Oct;586(7830):488-489 - PubMed
  4. Lancet. 2021 Mar 13;397(10278):1023-1034 - PubMed
  5. Science. 2020 Dec 4;370(6521):1227-1230 - PubMed
  6. Vaccine. 2016 May 27;34(25):2834-40 - PubMed
  7. Science. 2020 Aug 14;369(6505):812-817 - PubMed
  8. Head Neck. 2020 Jun;42(6):1303-1304 - PubMed
  9. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5133-8 - PubMed
  10. Nat Med. 2011 May;17(5):610-7 - PubMed
  11. Vaccine. 2018 Aug 28;36(36):5350-5357 - PubMed
  12. Cell. 2019 Sep 5;178(6):1313-1328.e13 - PubMed
  13. Vaccine. 2010 Nov 29;28(51):8077-84 - PubMed
  14. JAMA. 1985 Dec 13;254(22):3187-9 - PubMed
  15. Blood. 2011 Aug 4;118(5):1294-304 - PubMed
  16. Int J Obes (Lond). 2012 Aug;36(8):1072-7 - PubMed
  17. Vaccine. 2014 Feb 12;32(8):979-83 - PubMed
  18. Lancet. 2021 Mar 20;397(10279):1057-1058 - PubMed
  19. Semin Immunol. 2020 Aug;50:101422 - PubMed
  20. Discoveries (Craiova). 2013;1(1):e6 - PubMed
  21. J Immunol. 2015 Sep 1;195(5):2134-40 - PubMed
  22. Obesity (Silver Spring). 2016 Mar;24(3):615-25 - PubMed
  23. Clin Infect Dis. 2020 Dec 19;: - PubMed
  24. PLoS One. 2015 Jun 24;10(6):e0131531 - PubMed
  25. Int J Obes (Lond). 2017 Sep;41(9):1324-1330 - PubMed
  26. Clin Immunol. 2018 Aug;193:80-87 - PubMed
  27. N Engl J Med. 2021 May 20;384(20):1959-1961 - PubMed
  28. J Clin Microbiol. 2020 Aug 24;58(9): - PubMed
  29. Autoimmunity. 2006 Mar;39(2):137-41 - PubMed
  30. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  31. N Engl J Med. 2020 Dec 17;383(25):2439-2450 - PubMed
  32. Obes Res Clin Pract. 2018 Nov - Dec;12(6):513-519 - PubMed
  33. Lancet. 2021 Mar 6;397(10277):875-877 - PubMed

Publication Types